1-Aminobenzotriazole coincubated with (s)-warfarin results in potent inactivation of CYP2C9s

Drug Metabolism and Disposition

Volumn 42, Issue 5, 2014, Pages 813-817

  Sodhi, Jasleen K ^a   Ford, Kevin A ^a   Mukadam, Sophie ^a   Wong, Susan ^a   Hop, Cornelis E C A ^a   Khojasteh, S Cyrus ^a   Halladay, Jason S ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 AMINOBENZOTRIAZOLE; CYTOCHROME P450 2C9; DICLOFENAC; WARFARIN; 1-AMINOBENZOTRIAZOLE; CYP2C9 PROTEIN, HUMAN; PROTEIN BINDING; TRIAZOLE DERIVATIVE;

ARTICLE; COMPUTER MODEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING; DRUG POTENCY; ENZYME ACTIVE SITE; ENZYME INACTIVATION; ENZYME KINETICS; FEMALE; HUMAN; IN VITRO STUDY; MALE; PRIORITY JOURNAL; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; ENZYME SPECIFICITY; ENZYMOLOGY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MOLECULAR DOCKING; TANDEM MASS SPECTROMETRY; TIME;

BINDING SITES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP2C9; DICLOFENAC; FEMALE; HUMANS; IN VITRO TECHNIQUES; MALE; MICROSOMES, LIVER; MOLECULAR DOCKING SIMULATION; MOLECULAR STRUCTURE; PROTEIN BINDING; SUBSTRATE SPECIFICITY; TANDEM MASS SPECTROMETRY; TIME FACTORS; TRIAZOLES; WARFARIN;

EID: 84898813976     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.055913     Document Type: Article

References (26)

1. Emoto C, Murase S, Sawada Y, and Iwasaki K (2005) In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations in human liver microsomes: a comparison with SKF-525A. Drug Metab Pharmacokinet 20:351-357.
2. Emoto C, Murase S, Sawada Y, Jones BC, and Iwasaki K (2003) In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations catalyzed by human cytochrome P450 enzymes: a comparison with SKF-525A and ketoconazole. Drug Metab Pharmacokinet 18: 287-295.
3. Freire E (2008) Do enthalpy and entropy distinguish first in class from best in class? Drug Discov Today 13:869-874.
4. Halladay JS, Delarosa EM, Tran D, Wang L, Wong S, and Khojasteh SC (2011) High-throughput, 384-well, LC-MS/MS CYP inhibition assay using automation, cassette-analysis technique, and streamlined data analysis. Drug Metab Lett 5:220-230.
5. Humphrey W, Dalke A, and Schulten K (1996) VMD: visual molecular dynamics. J Mol Graph 14:33-38, 27-28.
6. Hutzler JM, Balogh LM, Zientek M, Kumar V, and Tracy TS (2009) Mechanism-based inactivation of cytochrome P450 2C9 by tienilic acid and (+/-)-suprofen: a comparison of kinetics and probe substrate selection. Drug Metab Dispos 37:59-65.
7. Kaminsky LS and Zhang ZY (1997) Human P450 metabolism of warfarin. Pharmacol Ther 73: 67-74.
8. Kenworthy KE, Bloomer JC, Clarke SE, and Houston JB (1999) CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br J Clin Pharmacol 48:716-727.
9. Korzekwa KR, Krishnamachary N, Shou M, Ogai A, Parise RA, Rettie AE, Gonzalez FJ, and Tracy TS (1998) Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 37:4137-4147.
10. Kumar V, Wahlstrom JL, Rock DA, Warren CJ, Gorman LA, and Tracy TS (2006) CYP2C9 inhibition: impact of probe selection and pharmacogenetics on in vitro inhibition profiles. Drug Metab Dispos 34:1966-1975.
11. Leemann T, Transon C, and Dayer P (1993) Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 49-hydroxylation in human liver. Life Sci 52:29-34.
12. Linder CD, Renaud NA, and Hutzler JM (2009) Is 1-aminobenzotriazole an appropriate in vitro tool as a nonspecific cytochrome P450 inactivator? Drug Metab Dispos 37:10-13.
13. MacKerell Jr AD, Banavali N, and Foloppe N (2000-2001) Development and current status of the CHARMM force field for nucleic acids. Biopolymers 56:257-265.
14. Melet A, Assrir N, Jean P, Pilar Lopez-Garcia M, Marques-Soares C, Jaouen M, Dansette PM, Sari MA, and Mansuy D (2003) Substrate selectivity of human cytochrome P450 2C9: importance of residues 476, 365, and 114 in recognition of diclofenac and sulfaphenazole and in mechanism-based inactivation by tienilic acid. Arch Biochem Biophys 409:80-91.
15. Miners JO and Birkett DJ (1998) Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 45:525-538.
16. Ortiz de Montellano PR and Mathews JM (1981) Autocatalytic alkylation of the cytochrome P-450 prosthetic haem group by 1-aminobenzotriazole. Isolation of an NN-bridged benzyneprotoporphyrin IX adduct. Biochem J 195:761-764.
17. Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, Aoyama T, Gelboin HV, Gonzalez FJ, and Trager WF (1992) Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 5:54-59.
18. Schrag ML and Wienkers LC (2001) Covalent alteration of the CYP3A4 active site: evidence for multiple substrate binding domains. Arch Biochem Biophys 391:49-55.
19. Seifert A, Tatzel S, Schmid RD, and Pleiss J (2006) Multiple molecular dynamics simulations of human P450 monooxygenase CYP2C9: the molecular basis of substrate binding and regioselectivity toward warfarin. Proteins 64:147-155.
20. Shou M, Mei Q, Ettore MW, Jr, Dai R, Baillie TA, and Rushmore TH (1999) Sigmoidal kinetic model for two co-operative substrate-binding sites in a cytochrome P450 3A4 active site: an example of the metabolism of diazepam and its derivatives. Biochem J 340:845-853.
21. Strelevitz TJ, Foti RS, and Fisher MB (2006) In vivo use of the P450 inactivator 1-aminobenzotriazole in the rat: varied dosing route to elucidate gut and liver contributions to first-pass and systemic clearance. J Pharm Sci 95:1334-1341.
22. Takahashi H and Echizen H (2001) Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet 40:587-603.
23. U.S. Department of Health and Human Services, Food and Drug Administration (September 2006) Guidance for Industry: Drug Interaction Studies-Study Design, Data Analysis, and Implications for Dosing and Labeling.
24. Wang YH, Jones DR, and Hall SD (2004) Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos 32:259-266.
25. Williams PA, Cosme J, Ward A, Angove HC, Matak Vinkovic D, and Jhoti H (2003) Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature 424:464-468.
26. Yan Z, Li J, Huebert N, Caldwell GW, Du Y, and Zhong H (2005) Detection of a novel reactive metabolite of diclofenac: evidence for CYP2C9-mediated bioactivation via arene oxides. Drug Metab Dispos 33:706-713.